RFK Jr. Discovers Peptides, VCs Discover Regulatory Capture

The machinery is in motion. RFK Jr., newly installed as Health Secretary and freshly equipped with a mission to 'loosen federal restrictions' on peptides, has accidentally created the most investor-friendly conditions imaginable: a federally-blessed deregulation tailwind targeting 'heavily touted but loosely regulated proteins.' Telehealth companies, compounding pharmacies, and longevity clinics are already limbering up their Series C decks. The deal? Minimal oversight + maximum hype + existing distribution networks = the next wellness boom. What could possibly go wrong?

The framing is exquisite. This isn't regulatory capture dressed in a Hermès suit. This is regulatory capture *dressed as wellness*. Peptides—compounds that exist in a regulatory gray zone—suddenly become venture-fundable because the guy running health policy has decided they should be. The irony that 'heavily touted' is Axios-speak for 'we have no idea if this works' seems to have escaped every founder in a 50-mile radius of Sand Hill Road.

The press release writes itself: 'We're not selling snake oil, we're democratizing access to scientifically-adjacent biohacking infrastructure.' Telehealth plays it as expanding options. Compounders frame it as liberation. Longevity clinics—already operating in the shadows of plausibility—suddenly have federal tailwinds. The 'why it matters' section of every pitch deck just became 'regulatory clarity from the top.'

By next quarter, expect seventeen new unicorn announcements. By 2026, expect congressional hearings. The VCs, as always, will be long gone.